Clinical Trials Sponsored by LCA Pharmaceutical

Total 27770 results

Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%

Osteo Arthritis of the Knee

United States
La Jolla Pharmaceutical Company

Terminated

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Beta-Thalassemia

Australia, Thailand, United States, Greece, Italy, Lebanon, Turkey, United Kingdom
La Jolla Pharmaceutical Company

Terminated

A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

Hepatorenal Syndrome Type I and Type II

United States
La Jolla Pharmaceutical Company

Withdrawn

Study of LJP 394 (Abetimus Sodium) in Lupus Patients

Systemic Lupus Erythematosus

United States
La Jolla Pharmaceutical Company

Withdrawn

A Phase 2 Extension of Study GCS-100-CS-4003

Chronic Kidney Disease

United States
La Jolla Pharmaceutical Company

Completed

Safety Study of GCS-100 to Treat Chronic Kidney Disease

Chronic Kidney Disease

United States
Unither Pharmaceuticals, France
International Pharmaceutical Research Center

Completed

Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)

Healthy

Jordan
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Amneal Pharmaceuticals, LLC
Novum Pharmaceutical Research Services

Completed

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
Kuhnil Pharmaceutical Co., Ltd.
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

Sleep Initiation and Maintenance Disorders

Korea, Republic of
La Jolla Pharmaceutical Company

Recruiting

A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock

Septic Shock | Catecholamine-resistant Hypotension (CRH) | Distributive Shock | High Output Shock

Belgium, Lithuania
La Jolla Pharmaceutical Company

Completed

A Study of LJPC-501 in Pediatric Patients With Hypotension

Sepsis | Catecholamine-resistant Hypotension (CRH) | Distributive Shock | High Output Shock

United States
La Jolla Pharmaceutical Company

Completed

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (ATHOS-3)

Sepsis | Catecholamine-resistant Hypotension (CRH) | Distributive Shock | High Output Shock

United States, Canada, Belgium, Australia, United Kingdom, Finland, New Zealand, France, Switzerland, Germany
La Jolla Pharmaceutical Company

Approved for marketing

Expanded Access for LJPC-501

Sepsis | Vasodilatory Shock | Distributive Shock | High Output Shock | Catecholamine Resistant Hypotension (CRH)
La Jolla Pharmaceutical Company

Completed

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

Chronic Kidney Disease

United States
La Jolla Pharmaceutical Company

Terminated

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

Multiple Myeloma

United States
La Jolla Pharmaceutical Company

Withdrawn

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (GCS-100LE)

Diffuse Large B-cell Lymphoma

United States
La Jolla Pharmaceutical Company

Completed

Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia (PR-CS008)

Chronic Lymphocytic Leukemia

United States
La Jolla Pharmaceutical Company

Completed

A Phase 2 Extension Study of Study GCS-100-CS-4002

Chronic Kidney Disease

United States
La Jolla Pharmaceutical Company

Unknown

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Diabetic Chronic Kidney Disease

United States
La Jolla Pharmaceutical Company

Terminated

Study of LJP 394 in Lupus Patients With History of Renal Disease (ASPEN)

Lupus Erythematosus, Systemic | Lupus Nephritis

Taiwan, United States, Belarus, Serbia, Czech Republic, Philippines, Lebanon, India, Korea, Republic of, Argentina, Australia, Brazil, Bulgaria, Georgia, Germany, Hong Kong, Hungary, Indonesia, Italy, Malaysia, Mexico, Poland, Portugal and more
La Jolla Pharmaceutical Company

Completed

Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

Autoimmune Diseases | Systemic Lupus Erythematosus | Lupus Nephritis | Immunologic Diseases | Lupus Glomerulonephritis

United States, Austria, Canada, France, Germany, Italy, Mexico, Spain, Sweden, United Kingdom
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Lymphoma, Non-Hodgkin

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Completed

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Alzheimer's Disease

Japan
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Lee's Pharmaceutical Limited
Powder (Guangzhou) Pharmaceuticals Limited; Powder Pharmaceuticals (HK) Co....

Not yet recruiting

A Study of the Continuous Glucose Monitoring System for Home Use in Patients With Diabetes

Diabetes
Basilea Pharmaceutica
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients

Obesity | Streptococcal Infections | Staphylococcal Skin Infections
Basilea Pharmaceutica
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age

Streptococcal Infections | Staphylococcal Skin Infections
Tetraphase Pharmaceuticals, Inc.
Department of Health and Human Services

Completed

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women (BAL)

Normal Drug Tolerance

United States
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

Carcinoma, Hepatocellular

United States, Canada, Korea, Republic of, Taiwan, China, Puerto Rico, Japan, New Zealand, Belgium, Brazil, Spain, Germany, Poland, Thailand, Singapore, France, Turkey, Italy, United Kingdom, Mexico, Côte D'Ivoire, Hong Kong, Nigeria, South Africa
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Canada, United States, Korea, Republic of, Australia, Japan, Italy, Brazil, Germany, France, China, Israel
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Spain, United States, Germany, Estonia, Japan, Colombia, Turkey, Brazil, France, Greece, Poland, Taiwan, Netherlands, Saudi Arabia, Italy, Australia, Sweden, Singapore, Portugal, Hungary, Belgium, Canada, Czechia, Hong... and more
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

United States, Korea, Republic of, Malaysia, Turkey, Bulgaria, Canada, Poland, Puerto Rico, Romania, Croatia, Georgia, Italy, Philippines, Taiwan, Ukraine
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)

Hemophilia A

United States, France, Germany, Italy, South Africa, Spain, Turkey, Japan, United Kingdom, Costa Rica
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Gastric Cancer

Belgium, France, Italy, Spain, China, Costa Rica, Denmark, Germany, Portugal, Taiwan, United Kingdom, Russian Federation, Korea, Republic of, Peru, Turkey, Mexico, Australia, Brazil, Finland, Guatemala, India, Japan, Panama, South Africa
Tasly Pharmaceuticals, Inc.
Tasly Pharmaceutical Group Co., Ltd

No longer available

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Covid19

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Basilea Pharmaceutica
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease

Streptococcal Infections | Staphylococcal Skin Infections
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p)

Atypical Hemolytic Uremic Syndrome

United States, Belgium, China, France, Spain, Canada, South Africa, Japan, Brazil, Italy, Poland, India, Hungary, Mexico, Israel
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Australia, Korea, Republic of, Brazil, China, Japan, Turkey, Taiwan, Argentina, Germany, Italy, Russian Federation, Spain, France, Netherlands, Poland, Canada, Denmark
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER)

Paroxysmal Hemoglobinuria, Nocturnal

France, Korea, Republic of, Italy, Japan, Germany, Hungary, Netherlands
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

Macular Edema | Branch Retinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Neuromyelitis Optica (NMO) | NMO Spectrum Disorder (NMOSD)

Spain, Italy, United States, Japan, Poland, Taiwan, Germany, United Kingdom, Hungary, France, Ukraine

Clinical Trials Sponsored by LCA Pharmaceutical

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations